Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000076965 | SCV000301034 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-09-08 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Institute of Medical Genetics and Applied Genomics, |
RCV001543459 | SCV001762041 | pathogenic | not provided | 2021-06-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002362717 | SCV002658539 | pathogenic | Hereditary cancer-predisposing syndrome | 2017-03-06 | criteria provided, single submitter | clinical testing | The c.6405_6408delCTTA pathogenic mutation, located in coding exon 10 of the BRCA2 gene, results from a deletion of 4 nucleotides at nucleotide positions 6405 to 6408, causing a translational frameshift with a predicted alternate stop codon (p.N2135Kfs*32). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV002513809 | SCV003483473 | pathogenic | Hereditary breast ovarian cancer syndrome | 2024-12-29 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asn2135Lysfs*32) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with ovarian cancer (PMID: 29797126). ClinVar contains an entry for this variant (Variation ID: 91448). For these reasons, this variant has been classified as Pathogenic. |
Sharing Clinical Reports Project |
RCV000076965 | SCV000108762 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2009-01-27 | no assertion criteria provided | clinical testing |